BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 16088174)

  • 1. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T; Kapp A; Spergel J
    Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of topical calcineurin inhibitors in atopic dermatitis.
    Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
    Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
    Chen SL; Yan J; Wang FS
    J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
    Hebert AA
    Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
    Czarnecka-Operacz M; Jenerowicz D
    J Dtsch Dermatol Ges; 2012 Mar; 10(3):167-72. PubMed ID: 21974750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
    Ingram JR; Martin JA; Finlay AY
    Am J Clin Dermatol; 2009; 10(4):229-37. PubMed ID: 19489656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
    Kirsner RS; Heffernan MP; Antaya R
    Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential new indications of topical calcineurin inhibitors.
    Luger T; Paul C
    Dermatology; 2007; 215 Suppl 1():45-54. PubMed ID: 18174692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
    Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
    Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus ointment (Protopic) for atopic dermatitis.
    Pascual JC; Fleisher AB
    Skin Therapy Lett; 2004 Nov; 9(9):1-5. PubMed ID: 15550992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
    Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG
    Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema.
    Meurer M; Lubbe J; Kapp A; Schneider D
    Dermatology; 2007; 215 Suppl 1():18-26. PubMed ID: 18174690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New immune suppressants: topical immunomodulatory agents].
    Senatorski G; Sułowicz W; Paczek L
    Przegl Lek; 2002; 59(11):907-11. PubMed ID: 12715720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
    McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P; Ellis CN; Girolomoni G
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis.
    Bos JD
    Eur J Dermatol; 2003; 13(5):455-61. PubMed ID: 14693489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.